• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Xtant Medical inks licensing deal for Sites Medical’s OsteoSync Ti tech

Xtant Medical inks licensing deal for Sites Medical’s OsteoSync Ti tech

May 16, 2017 By Fink Densford

Xtant Medical, Sites Medical

Xtant Medical (NYSE:XTNT) said today it inked a licensing agreement with Sites Medical for its OsteoSync Ti porous titanium scaffold technology.

Sites Medical’s OsteoSync Ti technology is designed with a high friction coefficient for high implant stability and open pore geometry and micro-texturing for bone ingrowth, the company said.

“We are very excited to work with Sites Medical. As market dynamics shift towards emerging titanium technologies, Sites Medical’s OsteoSync Ti technology places us firmly at the forefront of this trend.  This technology exhibits great synergy with our entire line of spinal implants further enhancing the value of this relationship as well as Xtant’s potential impact in its core market,” Xtant Medical CEO Carl O’Connell said in a press release.

Data from preclinical testing indicated the OsteoSync Ti coating had bone attachment strength twice as strong as is found with titanium plasma sprays and 7 times as strong as PEEK material at 5-weeks post-procedure, the company said.

“We are thrilled to be partnering with Xtant Medical, a company with a rich history of innovation in the spine field. We look forward to working with the Xtant team to combine our respective technologies to deliver a new generation of high performance, high value products to the market,” Sites Medical prez & CEO Greg Stalcup said in a prepared statement.

Earlier this month, Xtant said it amended its senior credit line with OrbiMed Advisors, saying it plans to use the $15 million facility to pay off the $9 million it owes to Silicon Valley Bank.

The balance is earmarked for general working capital, the Belgrade, Mont.-based spinal implant maker said. Orbimed also deferred interest payments that were due in January and March to June 30, Xtant said.

Filed Under: Business/Financial News, Orthopedics Tagged With: sitesmedical, Xtant Medical

More recent news

  • Autonomix picks up key nerve ablation catheter patent
  • Affluent Medical can move to pivotal phase of artificial urinary sphincter study
  • Globus Medical announces $500M share repurchase program
  • Cook Medical warns of issue with angiographic catheter
  • Virtuoso Surgical reports first cases with robotic endoscopy system, plans FDA IDE submission

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy